IOM Proposals for Overhaul at CIRM Win High Marks
By David Jensen,
California Stem Cell Report
| 12. 07. 2012
[Quotes CGS's Marcy Darnovsky]
The Institute of Medicine's recommendations for major changes at the California stem cell agency today received generally high marks from independent observers and critics.
Many of the proposals echoed suggestions from California's Little Hoover Commission, the state's good government agency. Asked for comment, Stuart Drown, the commission's executive director, said,
“The institute’s recommendations for much-needed changes to CIRM’s governance structure to provide greater efficiency, clarity and accountability reinforce the recommendations the Little Hoover Commission made in 2009."
He continued,
“Then and now, the Commission’s recommendations are aimed at improving
CIRM’s ability to meet its goals for the good of all who can benefit
from stem cell research, and to ensure that California taxpayers’
dollars are put to their most efficient use to that end.”
The California Stem Cell Report also asked the agency's first president,
Zach Hall, for his thoughts. Here is the full text of what Hall, who
was one of the peer reviewers on the IOM study, had to say,
“The IOM Committee and its staff have done an impressive job. The
report recognizes the scientific value and...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...